Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that enrollment ... of this press release. While we may elect to update ... Read More

Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

March 29, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics ... formerly known as NASH) cirrhosis program. We completed enrollment and randomization for the NAVIGATE Phase 2b/3 trial in 2023, and ... Read More

Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors

The first patient was dosed in the Phase 1 dose escalation trial ... the Compass Therapeutics website at https://www.compasstherapeutics.com. Forward-Looking Statements This press release contains ... Read More

DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics ... today announced the first patient being dosed in DiaMedica’s relaunch of its pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the treatment ... Read More

Alyssum Therapeutics Announces First Patient Dosed in Phase 1/2 Study of AT-1965, a CMTR2 Inhibitor, in Solid Tumors

CAMBRIDGE, MA, USA, April 10, 2024 /EINPresswire.com/ -- Alyssum Therapeutics, a biotechnology company which is developing next-generation immunotherapies to modulate ... Read More

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

Infections are a leading cause of mortality and morbidity in this immunocompromised patient population. SER-155 is also designed ... of this press release. While we may elect to update such ... Read More

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

SER-155 is also designed to induce immune tolerance responses to reduce the incidence of GvHD. “We are pleased to complete enrollment in Cohort 2 of our SER-155 Phase 1b ... the date of this press ... Read More

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

MCRB), a leading microbiome therapeutics company, announced today that enrollment is complete in the placebo-controlled Cohort 2 of its Phase 1b trial of SER-155 in patients who received ... Read More